Jerusalem, May 8 (IANS) Israeli researchers have identified a genetic “fingerprint” that helps predict the effectiveness of immunotherapy treatments, according to a study.
The study, by the Israel Institute of Technology (Technion), stated that the discovery would help improve the personalisation of immunotherapy treatments, Xinhua news agency reported.
Immunotherapy is considered to be one of the greatest revolutions in cancer treatment. It enhances the immune system’s ability to target and destroy cancer cells efficiently.
However, a major challenge in immunotherapy is the unpredictability of patient responses. Some patients do not benefit and may experience side effects without significant improvement.
Therefore, there is a need to identify biomarkers that can forecast the effectiveness of treatment based on the specific data of each patient.
In their study, published in the journal Cell Genomics, the team examined the genetic characteristics of T-cell clones — groups of multiplied immune T cells that specialise in targeting a specific threat once recognised — and their influence on treatment success.
To achieve the goal, the team conducted a large-scale meta-analysis using single-cell RNA sequencing and T-cell receptor sequencing data from cancer patients undergoing immunotherapy.
It was found that although these T-cell clones are present in both responsive and non-responsive patients, those who respond to immunotherapy display a distinct genetic signature in their T-cell clones, and the treatment boosts their immune activity.
Another major finding was that in non-responsive patients, some T-cell clones were simultaneously found both in the bloodstream and the tumour.
To achieve a better immune response, it is crucial to activating T-cell clones located solely within the tumour, rather than those present in both the tumour and the bloodstream, the researchers said.
They added that this discovery will enhance predictive capabilities and could lead to new treatment strategies that improve the effectiveness of immunotherapy.
–IANS
rvt/
Disclaimer
The information contained in this website is for general information purposes only. The information is provided by BhaskarLive.in and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.
Through this website you are able to link to other websites which are not under the control of BhaskarLive.in We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
Every effort is made to keep the website up and running smoothly. However, BhaskarLive.in takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.
For any legal details or query please visit original source link given with news or click on Go to Source.
Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.
If you are not willing to accept this disclaimer then we recommend reading news post in its original language.
